Novavax, Inc.
- NVAX
- NASDAQ
- Biotechnology
- Vaccine Development
- COVID-19 Vaccine
$11.26
Today −12.17%Quote Oct 16, 2026, 08:00 PM UTC
+12.60%over the last month
Max drawdown −12.3%From 1-month high −12.2%3 months +42.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.86B
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$18.00
+59.9% from here
Floor
$10.89
3.3% below price
Where the price sits
23 analysts
Analyst range, low to high
$11.00$25.00
- Price $11.26
- Resistance $11.58–$11.69
- Consensus $18.00
The price is right under resistance. Analysts' average target sits about 60% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NVAXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $56.7M
- Licensing, Royalties, and Other$37.8M66.7%
- Royalties and Other$676,0001.2%
- Other / not reported$18.2M32.1%
Industry
Biotechnology
Employees
749